Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.70 |
| ▸ | PDE5A | O76074 | 11/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cipamfylline SCHEMBL26990 | 0.82 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7809025 | 0.82 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL13533471 | 0.80 | PDE5A (0.49) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL3188553 | 0.79 | PDE5A (0.45) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7027210 | 0.79 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL13986122 | 0.79 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL13986185 | 0.79 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7398584 | 0.78 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7025747 | 0.78 | ADORA1 (0.64) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL19583237 | 0.78 | PDE2A (0.44) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1120417-A2 | Xanthine derivatives for the treatment of cerebrovascular disorders | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 2001-08-01 | — | — | EP | claimed |
| US-5981535-A | FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-09 | — | — | US | claimed |
| US-5734051-A | TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY | BEECHAM GROUP (GB) | 1998-03-31 | — | — | US | claimed |
| EP-0389282-A2 | Xanthinederivatives, process for their preparation and their pharmaceutical use | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1990-09-26 | — | — | EP | claimed |
| US-6531600-B1 | 8-substituted xanthines have a protective effect against the consequences of cerebral metabolic inhibition; cerebral vascular and neuronal degenerative disorders; 6-aminouracil intermediate is claimed | BEECHAM GROUP P.L.C. (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1120417-A2 | Xanthine derivatives for the treatment of cerebrovascular disorders | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-6180791-B1 | REDUCING NITRO GROUPS TO FORM AMINO GROUPS | BEECHAM GROUP P.L.C. (GB) | 2001-01-30 | — | — | US | disclosed |
| US-5981535-A | FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-09 | — | — | US | disclosed |
| US-5734051-A | TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY | BEECHAM GROUP (GB) | 1998-03-31 | — | — | US | disclosed |
| EP-0550570-A1 | XANTHINE DERIVATIVES | Beecham Group p.l.c. (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992005175-A1 | XANTHINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1992-04-02 | — | — | WO | disclosed |
| EP-0389282-A2 | Xanthinederivatives, process for their preparation and their pharmaceutical use | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1990-09-26 | — | — | EP | disclosed |